Navigation Links
EMD Serono, Inc. Announces Expansion with Research Site in Cambridge, Massachusetts
Date:3/30/2009

ng plans still on track."

In 2008, EMD Serono announced a planned expansion of its Billerica laboratory to create a center of excellence in discovery, which is scheduled for completion in 2010. The Cambridge satellite laboratory, which will be approximately 18,000 square feet in size, will address the company's immediate need to secure necessary laboratory space for its additional scientists as a result of accelerated employee growth.

EMD Serono completed the first Phase III trial of an oral multiple sclerosis drug, cladribine, which is targeted for registration filing later this year. With these additional capabilities the company plans to focus research and development efforts towards Parkinson's disease, and other neurodegenerative diseases.

About EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives.

The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection) and Serostim(R) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alfa injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
2. iMedica Corporation Announces the Release of Patient Relationship Manager 2009
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
5. Thomson Reuters Announces 100 Top Hospitals Award Winners
6. iMedica Corporation Announces Release of Patient Relationship Manager 2009
7. KMSI Announces KMx Update That Provides eLearning, Knowledge Management and Collaboration Tools for Apple iPhone and Other Mobile Devices
8. Academy of Lymphatic Studies Announces Accelerated Hybrid Online Program
9. Human Pheromone Sciences Announces Fourth Quarter and Full Year Results
10. Nationwide Medical/Surgical Announces Availability of Tamiflu for the 2009-2010 Influenza Season
11. Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Botanica Day Spa has ... new and popular stem cell line from Pevonia®, ... wrinkles and naturally repairs the skin. The spa ... service by offering clients a complimentary dermaplaning session ... , Pevonia® continues to be a global leader ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Leaving the car at home and ... good for your health, a new study indicates. Researchers ... found that 76 percent of men and 72 percent of ... percent of women used public transit, and 14 percent of ... Those who drove to work weighed more and had higher ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, ... blocks. , Urbini, a new collection of versatile baby gear ... jogger to its lineup. , The Avi has been ... by the latest racing styles and a set of features ... offers a swift, smooth ride on runs, power-walks and causal ...
(Date:8/20/2014)... D.C. (PRWEB) August 20, 2014 ... received a five-year, $1.24 million Science Education Partnership ... Health to support NAHN’s collaborative project with the ... in Health Careers. , This collaborative NIH R25 ... for cultural and linguistic diversity among health professionals ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... BUFFALO, N.Y. -- The University at Buffalo announced today a ... and family to establish the Jacobs Institute, which will support ... of heart and vascular diseases. , ... was made in honor of Lawrence D. Jacobs, M.D., a ...
... 13 Market competition is,mounting to win ... most highly,qualified clinical investigators. Companies that develop ... their studies win an advantage in,bringing their ... white paper "Recruiting and Retaining,High-Quality Clinical Investigators" ...
... for recent disasters, WASHINGTON, June 13 The ... with relief efforts for,the victims of flooding and tornadoes ... West Virginia, the Red Cross is present,with vast amounts ... of,thousands of meals., Already, more than 1,400 Red ...
... Long and costly product,development cycles make it essential ... to the development of compounds with,the greatest potential ... and earlier into the new product process in ... development cycle,time, focus resources for greatest impact and ...
... lead to diagnostic urine test for 10% of men with ... traits of an aggressive type of prostate cancer that occurs ... been identified in hopes of finding a way to diagnose ... the Michigan Center for Translational Pathology at the University of ...
... June 2008: The TRAF1/C5 locus on chromosome 9 has ... diseases including type 1 diabetes and systemic lupus erythematosus ... 2008, the Annual Congress of the European League Against ... Factor-receptor associated factor 1) and C5 (complement component 5) ...
Cached Medicine News:Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 2Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 3Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 4Health News:American Red Cross Issues Appeal for Disaster Relief Fund 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2Health News:Researchers ID Traits of Aggressive Prostate Cancer 2Health News:Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases 2
(Date:8/20/2014)... -- Glenmark Pharmaceuticals S.A. (GPSA), a ... (GPL), announces the discovery and initiation of IND ... GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 ... Research Centre located in La Chaux-de-Fonds, ... Glenmark,s innovative BEAT antibody technology platform which facilitates ...
(Date:8/19/2014)... Aug. 19, 2014  The Alabama Supreme Court, in a ... sue drug makers who mislead doctors into believing that prescription ... case is Weeks v. Wyeth, and the decision came after ... same case last year. Heninger Garrison Davis attorneys Lew ... in the case, Danny Weeks . The ...
(Date:8/19/2014)... 2014 Minimally Invasive Devices Inc. (MID), a ... announced today that Mitsubishi Corporation has formally agreed to ... in Japan . MID anticipates that ... Japan in the second half of 2015. ... for Karl Storz GMBH & Co. (endoscopic instruments and ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... Corporation (NASDAQ: THOR ), a world leader ... and restore failing hearts, today announced that it will ... Wednesday, February 8. The company will hold ... operating activities, open to all interested parties, at 1:30 ...
... PuraMed BioScience, Inc. (OTCBB: PMBS) announced today that ... natural product for the treatment of migraine headaches, is ... Drug Chain in the United States. With the addition ... in approximately 15,000 stores nationwide. "We are ...
Cached Medicine Technology:Thoratec Schedules Fourth Quarter Conference Call, Webcast 2PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States 2
... AMO Prestige System marked an amazing ... of safety with high-performance fluidics.A.S.E.T. keeps ... conditions in the in the anterior ... the reaction and interaction of the ...
Highly versatile, efficient, compact and accurate digital readout display....
... system has all the features of phaco ... engineering means minimal maintenance. Small, light and ... to site. Lowest cost reusable tubing kit ... longer is there a price objection to ...
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Medicine Products: